Malignant Uterine Neoplasm — Trials

Malignant Uterine Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

3,291 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 824
Recruiting: 456
Ph III recruiting: 55
Growth YoY: −3.6%
Industry share: 24%
Top sponsor: National Cancer Institute (NCI)
Termination share: 25.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (333)

clinicaltrialsPublishedShowing 51–100 of 330 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03660826	Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone	active not recruiting	Phase 2	288	National Cancer Institute (NCI)NIH	2	Aug 28, 2026	clinicaltrials
NCT07793318	TR115 in ARID1A-Mutated Advanced Solid Tumors	not yet recruiting	Phase 2	50	Tarapeutics Science Inc.INDUSTRY